Seller record · Telehealth service

Aurelius Health Group

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S4, compounding disclosure: The home page describes shipment from compounding pharmacies but does not plainly disclose that its compounded protocol is not FDA-approved. 1 more criterion also fails; see the table below.

At a glance

Aurelius Health GroupTelehealth service

6/8criteria passed

Price: Printed on its own pages before sign-up
Sells: tirzepatide microdosing
FDA letters: None on file

Visit Aurelius Health Group See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform promoting a clinician-reviewed tirzepatide microdosing protocol with an introductory monthly price, a continuing rate and four named pharmacy partners.

Operating entity Aurelius Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Aurelius Health Group's website
S2	Prescription gating	PASS	Aurelius Health Group's website
S3	Pharmacy identification	PASS	Aurelius Health Group's terms of use page
S4	Compounding disclosure	FAIL	Aurelius Health Group's website
S5	Analytical documentation	FAIL	Aurelius Health Group's website; Aurelius Health Group's terms of use page
S6	Business address	PASS	Aurelius Health Group's HIPAA privacy policy
S7	Price disclosure	PASS	Aurelius Health Group's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA board-certified MD or DO reviews the medical questionnaire and designs the treatment protocol, with ongoing physician follow-up.Source: Aurelius Health Group's website.

S2PASSThe public sequence starts with a questionnaire covering medical history and medications, followed by physician review, a written plan and pharmacy shipment.Source: Aurelius Health Group's website.

S3PASSThe terms identify RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx with street addresses.Source: Aurelius Health Group's terms of use page.

S4FAILThe home page describes shipment from compounding pharmacies but does not plainly disclose that its compounded protocol is not FDA-approved.Source: Aurelius Health Group's website.

S5FAILThe program and legal pages publish no certificate of analysis or equivalent lot document for the protocol.Source: Aurelius Health Group's website; Aurelius Health Group's terms of use page.

S6PASSThe privacy page lists 317 6th Ave. Ste. 400, Des Moines, IA 50309 as the privacy contact address.Source: Aurelius Health Group's HIPAA privacy policy.

S7PASSThe home page advertises $89 for the first month and $199 a month afterward. Those figures describe the introductory and continuing prices, not a permanently discounted monthly rate.Source: Aurelius Health Group's website.

S8PASSNo FDA warning letter names Aurelius Health Group or Aurelius Health Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: tirzepatide microdosing.

Other sellers of the same products

Who sells tirzepatide

Visit Aurelius Health Group

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.